Menu Search
Equities

Adocia SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ADOC:PAR

Adocia SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)6.53
  • Today's Change-0.17 / -2.54%
  • Shares traded349.07k
  • 1 Year change+16.61%
  • Beta-0.1551
Data delayed at least 15 minutes, as of Feb 06 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The 3 analysts offering 12 month price targets for Adocia SA have a median target of 16.00, with a high estimate of 17.60 and a low estimate of 12.00. The median estimate represents a 145.02% increase from the last price of 6.53.
High169.5%17.60
Med145.0%16.00
Low83.8%12.00

Earnings history & estimates in EUR

Adocia SA reported annual 2024 losses of -0.51 per share on Apr 17, 2025.
Average growth rate+9.24%
More ▼

Revenue history & estimates in EUR

Adocia SA had revenues for the full year 2024 of 9.32m. This was 333.49% above the prior year's results.
Average growth rate+254.17%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.